Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19
|Date||July 23, 2020|
A randomized, open-label controlled trial of 504 patients with mild-to-moderate COVID-19 were treated with standard care, hydroxychloroquine or hydroxychloroquine plus azithromycin resulted in no difference in clinical status at 15 days.
Of note, the median time between symptoms onset and randomization was reported to be 7 days and included patients up to 14 days after symptom onset.
No revisions reported at this time.